Lexaria Bioscience (LEXX) Fundamental Analysis: Revenue, Earnings & Valuation

4.29 / 10

Netural

Fundamentally, LEXX is rated Neutral with a 4.3/10 score, indicating modest quality. Positive drivers include fixed‑asset turnover, low cost‑of‑sales and strong revenue growth, while income‑tax ratio and receivables turnover are weak. Composite fund score 4.29 reflects mixed factor contributions.

Analysis Checks(7/10)

Revenue-MV

Value-2.88

Score3/3

Weight43.13%

1M Return8.83%

Total operating revenue (YoY growth rate %)

Value52.05

Score2/3

Weight2.29%

1M Return0.58%

Inventory turnover ratio

Value106.57

Score3/3

Weight-2.45%

1M Return-0.67%

Accounts receivable turnover ratio

Value2.70

Score1/3

Weight-6.10%

1M Return-1.57%

PB-ROE

Value0.73

Score0/3

Weight17.73%

1M Return3.80%

Income tax / Total profit (%)

Value22.35

Score0/3

Weight-5.51%

1M Return-1.54%

Fixed assets turnover ratio

Value1.95

Score2/3

Weight-3.87%

1M Return-1.01%

Interest coverage ratio (EBIT / Interest expense) (%)

Value34.91

Score2/3

Weight-2.74%

1M Return-0.73%

Cost of sales ratio (%)

Value0.39

Score3/3

Weight3.41%

1M Return0.79%

Asset-MV

Value-0.55

Score2/3

Weight54.10%

1M Return9.91%

Is LEXX undervalued or overvalued?

LEXX scores 4.29/10 on fundamentals and holds a Fair valuation at present. Backed by its -44.76% ROE, 0.00% net margin, -1.73 P/E ratio, 4.13 P/B ratio, and -14.00% earnings growth, these metrics solidify its Netural investment rating.